Hofseth Biocare ASA (HBC) fair value: what the stock is really worth
We calculate from audited financials what Hofseth Biocare ASA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Hofseth Biocare ASA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range kr 1.12 – kr 8.08 · fair‑value band kr 1.70 – kr 2.84 · the kr 1.33 price screens below the kr 2.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 23, 2026.
Follow Hofseth Biocare in your weekly email
Every Wednesday you see whether Hofseth Biocare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States.
Show more
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.
Stock analysis
Hofseth Biocare ASA (HBC) currently trades at kr 1.33, while our model-based Fair Value estimate is kr 2.27, implying the stock looks roughly 41.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 1.70 (bear) to kr 2.84 (bull), the price of kr 1.33 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Hofseth Biocare ASA reported revenue of 256M NOK in FY2025 versus 87.6M NOK in FY2021, a compound +30.8%/yr. Reported net income was −135M NOK in FY2025.
Key figures
Market cap 651M NOK (≈ $68.2M) · P/S ratio 2.66 · EPS (TTM) kr −0.3400 · Net margin −52.6% · Return on equity −346% · Return on assets (EBIT) −29.6% · Operating margin −67.9% · Revenue (TTM) 245M NOK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 3% fair-value upside, at 71%, HBC screens cheaper than that median.
Notify me when HBC reaches fair value
Put HBC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.9%
Start year 2020 (pandemic). Over 10 years: +16.6% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.8%
’12
’13
’15
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−132.9% (2020) → −43.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 646 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside+70.7% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−19.9% · Bottom 25%
Net margin (TTM)−56.5% · Bottom 25%
Operating margin (TTM)−67.9% · Bottom 25%
Growth and dividend
Revenue growth−18.7% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.28× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 33
FUTURE (revenue growth)0· sector 19
PAST (return on equity)0· sector 30
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 58
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hofseth Biocare ASA (HBC) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of kr 2.27 versus a price of kr 1.33, about +71% upside (undervalued).
What is the fair value of HBC?
Our model-based fair value for Hofseth Biocare ASA is kr 2.27 (as of Jun 23, 2026), built from audited fundamentals. The current price: kr 1.33.
What is the quality score of HBC?
Hofseth Biocare ASA has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hofseth Biocare ASA (HBC)?
Our model-based price target is the fair value of kr 2.27 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario kr 1.70, optimistic scenario kr 2.84. It is a calculation from audited fundamentals, not an analyst target.
What is the Hofseth Biocare ASA stock forecast for 2026?
Our models put fair value at kr 2.27, about +71% upside versus a price of kr 1.33 (undervalued). Cautious scenario kr 1.70, optimistic scenario kr 2.84. The calculation is refreshed regularly with new filings.
What is the revenue of Hofseth Biocare ASA (HBC)?
Hofseth Biocare ASA reported trailing-twelve-month revenue of about 245M NOK (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Hofseth Biocare ASA (HBC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hofseth Biocare ASA it is kr 2.27 per share (as of Jun 23, 2026), against a price of kr 1.33. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Hofseth Biocare ASA stock overvalued or undervalued in 2026?
As of Jun 23, 2026, HBC trades below its calculated fair value: price kr 1.33, fair value kr 2.27, a gap of about +71% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HBC?
No. The price is what the market pays today (kr 1.33); the fair value is what the company's own numbers justify (kr 2.27). For Hofseth Biocare ASA the two are kr 0.9400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hofseth Biocare ASA worth?
The market values Hofseth Biocare ASA at about 651M NOK (market capitalisation, as of Jun 23, 2026). Per share that is kr 1.33; our models calculate a fair value of kr 2.27 per share.
What do the bullish and bearish scenarios say about HBC?
Our models span a range for Hofseth Biocare ASA: cautious scenario kr 1.70, base kr 2.27, optimistic kr 2.84 per share (as of Jun 23, 2026, price kr 1.33). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hofseth Biocare ASA (HBC)?
Balance-sheet figures for Hofseth Biocare ASA (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is HBC from its 52-week high?
Hofseth Biocare ASA trades at kr 1.33, about 36% below its 52-week high of kr 2.08 and 19% above the low of kr 1.12 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of kr 2.27 is for.
Which stocks are comparable to Hofseth Biocare ASA?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hofseth Biocare ASA stock attractive at the current price?
The data as of Jun 23, 2026: price kr 1.33, calculated fair value kr 2.27 (+71%), Quality Score 34/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HBC calculated?
We run Hofseth Biocare ASA through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 2.27, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. Hofseth Biocare ASA currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hofseth Biocare ASA (HBC)?
The closing price on Sep 29, 2026 was kr 1.33. Our model-based fair value is kr 2.27, about +71% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hofseth Biocare ASA right now?
The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (kr 1.70). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Hofseth Biocare ASA
How large is the market capitalisation of Hofseth Biocare ASA (HBC)?
The market capitalisation of Hofseth Biocare ASA is 651M NOK (≈ $68.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hofseth Biocare ASA (HBC)?
The price-to-sales ratio of Hofseth Biocare ASA is 2.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hofseth Biocare ASA (HBC)?
Earnings per share at Hofseth Biocare ASA are kr −0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hofseth Biocare ASA (HBC)?
The net margin of Hofseth Biocare ASA is −52.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hofseth Biocare ASA (HBC)?
The return on equity (ROE) of Hofseth Biocare ASA is −346% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hofseth Biocare ASA (HBC)?
On an EBIT basis the return on assets of Hofseth Biocare ASA is −29.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hofseth Biocare ASA (HBC)?
The operating margin of Hofseth Biocare ASA is −67.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hofseth Biocare ASA (HBC)?
Revenue at Hofseth Biocare ASA is growing −18.7% versus a year earlier (3y avg +28.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hofseth Biocare ASA (HBC) generate?
The free cash flow of Hofseth Biocare ASA is −41.7M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hofseth Biocare ASA (HBC) carry?
The net debt of Hofseth Biocare ASA is 191M NOK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hofseth Biocare ASA in the live analysis
One click puts Hofseth Biocare ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
